Is hormone ablation still the right choice for advanced prostate cancer?
Fitzpatrick
John M
JM
Department of Surgery, Mater Misericordiae Hospital, University College, Dublin, Ireland. jfitzpatrick@mater.ie
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000728:Androgens / Q000378:metabolism*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D008297:Male; D009919:Orchiectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000628:therapy*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D007987:Gonadotropin-Releasing Hormone